Browsed by
Tag: Fad drug approval

Ocrelizumab versus Rituximab (Rituxan)

Ocrelizumab versus Rituximab (Rituxan)

I decided to go a little honest about our pharmaceutical world of MS. There has been so much press and promise over this new drug coming out for multiple sclerosis. Put Ocrelizumab in your web search and you’ll get article after article about the promise of this new drug. NEWS FLASH!!!! Rituximab is Ocrelizumab The patent on Rituximab expired in the US in 2015. Basically when they were doing the clinical trials with multiple sclerosis by the time they were…

Read More Read More

Verified by MonsterInsights